Phase I Dose‐Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors

LESSONS LEARNED. Despite involvement of PI3K pathway activation in tumorigenesis of solid tumors, single‐agent PI3K inhibitors have shown modest clinical activity. Preclinical evidence suggests that combining PI3K pathway inhibitors and chemotherapy can enhance antitumor effects. In patients with so...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncologist
Auteurs principaux: Wheler, Jennifer, Mutch, David, Lager, Joanne, Castell, Christelle, Liu, Li, Jiang, Jason, Traynor, Anne M.
Format: Artigo
Langue:Inglês
Publié: AlphaMed Press 2017
Sujets:
Clinical Trial Results
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5388374/
https://ncbi.nlm.nih.gov/pubmed/28275119
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0257
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires